esuberaprost

Ligand id: 8314

Name: esuberaprost

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 86.99
Molecular weight 398.21
XLogP 3.43
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Esuberaprost is being assessed in Phase III clinical trial as a potential treatment for pulmonary arterial hypertension (in combination with treprostinil).
Mechanism Of Action and Pharmacodynamic Effects
Like the endogenous ligand prostacyclin, esuberaprost elicits potent vasodilation and inhibition of platelet aggregation through binding to the IP1 receptor.